Showing results (2881-2890 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|April 30, 2021
The drug lag issue: a 20-year review of ChinaXiaoyu Li, Yue Yang
Investigational New Drugs|April 28, 2021
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib studyKyaw Zin Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Investigational New Drugs|April 29, 2021
Comment on "Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma"Jiong Lin
Investigational New Drugs|April 29, 2021
Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancerMing-Jun Zhang, Dong-Sheng Chen, Si Li, et al.
Investigational New Drugs|May 21, 2021
Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II studyDaisuke Kotani, Takayuki Yoshino, Masahito Kotaka, et al.
Investigational New Drugs|May 17, 2020
Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancerSatoshi Igawa, Taihei Ono, Masashi Kasajima, et al.
Investigational New Drugs|June 14, 2020
The kinesin motor protein KIF4A as a potential therapeutic target in renal cell carcinomaGuihong Liu, Yachun Lu, Liantao Li, et al.
Investigational New Drugs|May 31, 2020
Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinomaBradley A McGregor, Michael Gordon, Ronan Flippot, et al.
Investigational New Drugs|August 6, 2022
An open-label, crossover study to compare different formulations and evaluate effect of food on pharmacokinetics of pimitespib in patients with advanced solid tumorsYoshito Komatsu, Tsuneo Shimokawa, Kohei Akiyoshi, et al.
Investigational New Drugs|September 14, 2021
Modulation of peritumoral fibroblasts with a membrane-tethered tissue inhibitor of metalloproteinase (TIMP) for the elimination of cancer cellsYihe Zhang, Shiyu Liu, Bingjie Jiang, et al.
Pageof 372